secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-08-28T20:06:46+00:00
Accession:  0001070081-26-000019
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics to acquire ST-920 gene therapy for Fabry disease from Sangamo for $111M upfront
--------------------------------------------------------------------------------

- Upfront $111M plus up to $100M milestones: $80M on FDA accelerated approval, $20M on full approval of ST-920 BLA.
- ST-920 is a one-time AAV gene therapy candidate for Fabry disease, acquired from Sangamo in bankruptcy auction.
- Closing subject to Bankruptcy Court approval (hearing Sept 10, 2026) and HSR waiting period; deadline Oct 15, 2026.
- PTC was selected as winning bidder in Sangamo's Chapter 11 case; agreement includes customary reps/warranties, no indemnification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/0001070081-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/tmb-20260825x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer